Frontier IP acquires 20% stake in University of Cambridge spin-out Tarsis Technology

Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that it has received a 20% stake in Tarsis Technology Limited (“Tarsis”), the Group’s third spin-out from the Department of Chemical Engineering and Biotechnology at the University of Cambridge.

Tarsis plans to develop and commercialise technology created by Dr David Fairen-Jimenez, a Royal Society University Research Fellow at the Department of Chemical Engineering and Biotechnology at the University of Cambridge, and his research team. The technology allows slower and more controlled delivery of drugs using metal-organic frameworks (MOFs). The pharmaceutical industry has demonstrated early interest in the technology.

Frontier IP brings experience in commercialising IP and relationships with key players in relevant markets. Dr Fairen-Jimenez’s technology approach combined with our support and network in the pharmaceutical space can help accelerate the commercialisation for this exciting technology.

Dr Campbell Wilson, Director of Tarsis

Frontier IP’s role will be to provide commercialisation services and in-depth pharmaceutical industry expertise. Dr Campbell Wilson, a non-executive director of Frontier IP, has been appointed as a non-executive director of Tarsis. Dr Wilson is currently a member (and past chairman) of the Board of the UK Pharmaceutical Licensing Group and has worked in the pharmaceutical industry for over 35 years.

Dr Campbell Wilson, Non-Executive Director of Frontier IP and Director of Tarsis, said: “We are looking forward to working with Dr Fairen-Jimenez on this promising opportunity. Frontier IP brings experience in commercialising IP and relationships with key players in relevant markets. Dr Fairen-Jimenez’s technology approach combined with our support and network in the pharmaceutical space can help accelerate the commercialisation for this exciting technology.”

Dr David Fairen-Jimenez, Chief Executive of Tarsis, said: “This is a great opportunity to see the state-of-the-art materials we prepare in our labs move into the market. The synergy between Frontier IP and their experience in new ventures and in the pharmaceutical industry combined with our leading work in advanced materials for drug delivery will give a strong commercial dimension to this project.”

Tags: , , , ,